Mark Jacobson's most recent trade in Axsome Therapeutics Inc was a trade of 35,378 Common Stock done at an average price of $2.8 . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.85 per share. | 26 Feb 2026 | 35,378 | 35,378 (0%) | 0% | 2.8 | 100,827 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 161.88 per share. | 26 Feb 2026 | 35,378 | 0 (0%) | 0% | 161.9 | 5,726,991 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 35,378 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 19,663 | 19,663 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.85 per share. | 22 Sep 2025 | 10,000 | 10,000 (0%) | 0% | 2.9 | 28,500 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2025 | 10,000 | 35,378 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 115.96 per share. | 22 Sep 2025 | 10,000 | 0 (0%) | 0% | 116.0 | 1,159,600 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 114.23 per share. | 16 Sep 2025 | 40,000 | 0 (0%) | 0% | 114.2 | 4,569,200 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.95 per share. | 16 Sep 2025 | 25,000 | 25,000 (0%) | 0% | 5.0 | 123,750 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2025 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.85 per share. | 16 Sep 2025 | 15,000 | 40,000 (0%) | 0% | 4.9 | 72,750 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 116.19 per share. | 16 Sep 2025 | 5,783 | 0 (0%) | 0% | 116.2 | 671,927 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.02 per share. | 09 Jun 2025 | 25,000 | 30,783 (0%) | 0% | 8.0 | 200,500 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 110.44 per share. | 09 Jun 2025 | 25,000 | 5,783 (0%) | 0% | 110.4 | 2,761,000 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.47 per share. | 27 May 2025 | 20,673 | 26,456 (0%) | 0% | 6.5 | 133,754 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2025 | 20,673 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 104.66 per share. | 27 May 2025 | 20,673 | 5,783 (0%) | 0% | 104.7 | 2,163,636 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 103.45 per share. | 27 May 2025 | 20,000 | 5,783 (0%) | 0% | 103.5 | 2,069,000 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.47 per share. | 27 May 2025 | 20,000 | 25,783 (0%) | 0% | 6.5 | 129,400 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,875 | 10,875 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,769 | 10,769 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 10,769 | 10,769 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 47,739 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.04 per share. | 09 Aug 2024 | 47,739 | 53,522 (0%) | 0% | 4.0 | 192,866 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 84.26 per share. | 09 Aug 2024 | 47,739 | 5,783 (0%) | 0% | 84.3 | 4,022,488 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 29 May 2024 | 13,693 | 13,693 (0%) | 0% | 1.3 | 17,801 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 13,693 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 74.31 per share. | 29 May 2024 | 7,910 | 5,783 (0%) | 0% | 74.3 | 587,813 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 01 Apr 2024 | 24,662 | 24,662 (0%) | 0% | 1.3 | 32,061 | Common Stock |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 24,662 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 77.24 per share. | 01 Apr 2024 | 24,662 | 0 (0%) | 0% | 77.2 | 1,904,942 | Common Stock |
| Axsome Therapeutics Inc | Jacobson Mark | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 32,825 | 32,825 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 18,027 | 18,027 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 41,424 | 41,424 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 23,491 | 23,491 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 89,405 | 89,405 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 47,990 | 47,990 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Jacobson | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 41,638 | 41,638 | - | - | Employee Stock Option (Right to Buy) |